A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer.

Trial Profile

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Denosumab (Primary) ; Zoledronic acid
  • Indications Bone metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 19 May 2015 Results ( bone turnover markers and outcomes) presented at the 110th Annual Meeting of the American Urological Association.
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 30 May 2014 Subgroup analysis results for primary endpoint (time to SRE) published in the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top